Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology

Chera L. Maarouf, Thomas G. Beach, Charles H. Adler, Michael Malek-Ahmadi, Tyler A. Kokjohn, Brittany Dugger, Douglas G. Walker, Holly A. Shill, Sandra A. Jacobson, Marwan N. Sabbagh, Alex E. Roher

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Identifying biomarkers that distinguish Parkinson's disease (PD) from normal control (NC) individuals has the potential to increase diagnostic sensitivity for the detection of early-stage PD. A previous proteomic study identified potential biomarkers in post- mortem ventricular cerebrospinal fluid (V-CSF) from neuropathologically diagnosed PD subjects lacking Alzheimer's disease (AD) neuropathology. In the present study, we assessed these biomarkers as well as p-tau181, Aβ42, and S100B by ELISA in PD (n = 43) and NC (n = 49) cases. The p-tau181/Aβ42 ratio and ApoA-1 showed statistically significant differences between groups. Multiple regression analysis demonstrated that p-tau181/Aβ42 had a significant odds ratio: OR = 1.42 (95% confidence interval [CI], 1.12-1.84), P = 0.006. Among the molecules investigated, intriguing correlations were observed that require further investigation. Our results suggest co- existent AD CSF biomarkers within the PD group notwithstanding that it was selected to minimize AD neuropathological lesions.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalBiomarker Insights
Volume8
DOIs
StatePublished - Mar 25 2013
Externally publishedYes

Keywords

  • Apolipoprotein A-1
  • Biomarkers
  • P-tau/aβ42 ratio
  • Parkinson's disease
  • Ventricular cerebrospinal fuid

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology'. Together they form a unique fingerprint.

Cite this